{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:26:22Z","timestamp":1792099582402,"version":"4.4.0"},"reference-count":47,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T00:00:00Z","timestamp":1705536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematology Reports"],"abstract":"<jats:p>Mantle cell lymphoma (MCL) prognosis has significantly improved in recent years; however, the possible survival benefit of new treatment options should be evaluated outside of clinical trials. We investigated 73 consecutive MCL patients managed from 2006 to 2020. For younger patients &lt;65 years old, the median PFS was 72 months and we reported a 2-year, 5-year, and 10-year PFS of 73%, 62%, and 41%; median OS was not reached and we reported a 2-year, 5-year, and 10-year OS of 88%, 82%, and 66%. For patients aged 75 years or older, the median PFS was 36 months and we reported a 2-year, 5-year, and 10-year PFS of 52%, 37%, and 37%; median OS was not reached and we reported a 2-year, 5-year, and 10-year OS of 72%, 55%, and 55%. The median PFS was significantly reduced for patients treated between 2006 and 2010 compared to patients treated between 2011 and 2015 (p = 0.04). Interestingly, there was a trend towards improved OS for patients treated between 2016 and 2020 compared to between 2006 and 2010 and between 2011 and 2015 (5-year OS was 91%, 44%, and 33%). These findings could be due to the introduction of BR as a first-line regimen for elderly patients and to the introduction of ibrutinib as a second-line regimen.<\/jats:p>","DOI":"10.3390\/hematolrep16010006","type":"journal-article","created":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T05:46:44Z","timestamp":1705643204000},"page":"50-62","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Survival Outcomes of Patients with Mantle Cell Lymphoma: A Retrospective, 15-Year, Real-Life Study"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0432-9706","authenticated-orcid":false,"given":"Emanuele","family":"Cencini","sequence":"first","affiliation":[{"name":"Unit of Hematology, Azienda Ospedaliera Universitaria Senese, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5426-5985","authenticated-orcid":false,"given":"Natale","family":"Calomino","sequence":"additional","affiliation":[{"name":"Unit of General Surgery and Surgical Oncology, Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Franceschini","sequence":"additional","affiliation":[{"name":"Unit of Hematology, Azienda Ospedaliera Universitaria Senese, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreea","family":"Dragomir","sequence":"additional","affiliation":[{"name":"Unit of Hematology, Azienda Ospedaliera Universitaria Senese, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Fredducci","sequence":"additional","affiliation":[{"name":"Unit of Hematology, Azienda Ospedaliera Universitaria Senese, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Esposito Vangone","sequence":"additional","affiliation":[{"name":"Unit of Hematology, Azienda Ospedaliera Universitaria Senese, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Lucco Navei","sequence":"additional","affiliation":[{"name":"Unit of Hematology, Azienda Ospedaliera Universitaria Senese, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2603-9715","authenticated-orcid":false,"given":"Alberto","family":"Fabbri","sequence":"additional","affiliation":[{"name":"Unit of Hematology, Azienda Ospedaliera Universitaria Senese, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3538-3913","authenticated-orcid":false,"given":"Monica","family":"Bocchia","sequence":"additional","affiliation":[{"name":"Unit of Hematology, Azienda Ospedaliera Universitaria Senese, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/hon.3149","article-title":"Mantle cell lymphoma-Update on molecular biology, prognostication and treatment approaches","volume":"41","author":"Silkenstedt","year":"2023","journal-title":"Hematol. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1080\/10428194.2023.2227748","article-title":"Treatment of older patients with mantle cell lymphoma in the era of novel agents","volume":"64","author":"Rozental","year":"2023","journal-title":"Leuk. Lymphoma"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.clml.2023.05.003","article-title":"SOHO State of the Art Updates and Next Questions: Tailoring Upfront Therapy in Mantle Cell Lymphoma","volume":"23","author":"Patel","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"iv62","DOI":"10.1093\/annonc\/mdx223","article-title":"Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Dreyling","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s11912-021-01094-y","article-title":"Leukemic Variant of Mantle Cell Lymphoma: Clinical Presentation and Management","volume":"23","author":"Isaac","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s13046-017-0652-8","article-title":"Smoldering mantle cell lymphoma","volume":"36","author":"Ye","year":"2017","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e13741","DOI":"10.1097\/MD.0000000000013741","article-title":"Simplified MIPI-B prognostic stratification method can predict the outcome well\u2014Retrospective analysis of clinical characteristics and management of newly-diagnosed mantle cell lymphoma patients from China","volume":"98","author":"He","year":"2019","journal-title":"Medicine"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1038\/s41375-023-01977-y","article-title":"Clinical outcome of Mantle Cell Lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression)","volume":"37","author":"Scheubeck","year":"2023","journal-title":"Leukemia"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","article-title":"Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): A randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma","volume":"377","author":"Thieblemont","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1182\/bloodadvances.2023009744","article-title":"Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCL","volume":"7","author":"Tisi","year":"2023","journal-title":"Blood Adv."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1200\/JCO.18.00605","article-title":"First-Line Treatment of Patients with Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma with Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study","volume":"37","author":"Flinn","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/bjh.15582","article-title":"Study of gene polymorphisms as predictors of treatment efficacy and toxicity in patients with indolent non-hodgkin lymphomas and mantle cell lymphoma receiving bendamustine and rituximab","volume":"184","author":"Cencini","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S1470-2045(18)30685-5","article-title":"Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: Final overall survival results of a randomised, open-label, phase 3 study","volume":"19","author":"Robak","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bjh.14241","article-title":"15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): Prolonged remissions without survival plateau","volume":"175","author":"Eskelund","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1080\/14656566.2018.1561865","article-title":"Lenalidomide for the treatment of mantle cell lymphoma","volume":"20","author":"Morabito","year":"2019","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigator\u2019s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/bjh.16739","article-title":"The 5-year follow-up of a real-world observational study of patients in the United Kingdom and Ireland receiving ibrutinib for relapsed\/refractory mantle cell lymphoma","volume":"192","author":"Tucker","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1182\/blood.2022015560","article-title":"Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse","volume":"140","author":"Rusconi","year":"2022","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/hon.2983","article-title":"Use of BTK inhibitors with focus on ibrutinib in mantle cell lymphoma: An expert panel opinion statement","volume":"40","author":"Zinzani","year":"2022","journal-title":"Hematol. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/bjh.14870","article-title":"Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: A pooled analysis from three open-label studies","volume":"179","author":"Rule","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41375-020-01013-3","article-title":"Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: Results from the MANTLE-FIRST study","volume":"35","author":"Visco","year":"2021","journal-title":"Leukemia"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1038\/s41375-022-01658-2","article-title":"Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial","volume":"36","author":"Freeman","year":"2022","journal-title":"Leukemia"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","article-title":"Postibrutinib outcomes in patients with mantle cell lymphoma","volume":"127","author":"Martin","year":"2016","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12943-023-01755-5","article-title":"CAR T-Cell therapy for the management of mantle cell lymphoma","volume":"22","author":"Huang","year":"2023","journal-title":"Mol. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.22.01797","article-title":"Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results from the US Lymphoma CAR T Consortium","volume":"41","author":"Wang","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/bjh.18597","article-title":"Survival of patients with mantle cell lymphoma in the rituximab era: Retrospective binational analysis between 2000 and 2020","volume":"201","author":"Harmanen","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"588314","DOI":"10.3389\/fonc.2020.588314","article-title":"Survival trends in patients under age 65 years with mantle cell lymphoma, 1995-2016: A SEER-based analysis","volume":"10","author":"Wu","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"13204","DOI":"10.1002\/cam4.6009","article-title":"Real-world treatment and outcome patterns of patients with mantle cell lymphoma in China: A large, multicenter retrospective analysis","volume":"12","author":"Yang","year":"2023","journal-title":"Cancer Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/annonc\/mds643","article-title":"ESMO Consensus conferences: Guidelines on malignant lymphoma. part 2: Marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma","volume":"24","author":"Dreyling","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2009-02-179739","article-title":"How I treat mantle cell lymphoma","volume":"114","author":"Ghielmini","year":"2009","journal-title":"Blood."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/hon.2825","article-title":"Direct-acting antivirals in hepatitis C virus-positive mantle cell lymphomas","volume":"39","author":"Merli","year":"2021","journal-title":"Hematol. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1200\/JCO.19.01294","article-title":"Treatment of Older Patients with Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial","volume":"38","author":"Hoster","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.3324\/haematol.2018.205229","article-title":"Ibrutinib for the treatment of relapsed\/refractory mantle cell lymphoma: Extended 3.5-year follow up from a pooled analysis","volume":"104","author":"Rule","year":"2019","journal-title":"Haematologica"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1080\/10428194.2023.2232490","article-title":"The prognostic role of gene polymorphisms in patients with indolent non-Hodgkin lymphomas and mantle-cell lymphoma receiving bendamustine and rituximab: Results of the 5-year follow-up study","volume":"64","author":"Cencini","year":"2023","journal-title":"Leuk. Lymphoma"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/ijc.34412","article-title":"Bendamustine and rituximab is well-tolerated and efficient in the treatment of indolent non-Hodgkin\u2019s lymphoma and mantle cell lymphoma in elderly: A single center observational study","volume":"152","author":"Kotchetkov","year":"2023","journal-title":"Int. J. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"6083","DOI":"10.21873\/anticanres.16120","article-title":"Bendamustine Plus Rituximab for Mantle Cell Lymphoma: A Korean, Multicenter Retrospective Analysis","volume":"42","author":"Yi","year":"2022","journal-title":"Anticancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/jha2.311","article-title":"Mantle cell lymphoma treatment options for elderly\/unfit patients: A systematic review","volume":"3","author":"Alnassfan","year":"2021","journal-title":"EJHaem"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Bega, G., Olivieri, J., Riva, M., Scapinello, G., Paolini, R., Finotto, S., Sartori, R., Lucchini, E., Guandalini, G., and Facchinelli, D. (2021). Rituximab and Bendamustine (BR) Compared with Rituximab, Bendamustine, and Cytarabine (R-BAC) in Previously Untreated Elderly Patients with Mantle Cell Lymphoma. Cancers, 13.","DOI":"10.3390\/cancers13236089"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e712","DOI":"10.1097\/HS9.0000000000000712","article-title":"Long-term Outcomes with Ibrutinib Treatment for Patients with Relapsed\/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials with Nearly 10 Years of Follow-up","volume":"6","author":"Dreyling","year":"2022","journal-title":"Hemasphere"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1002\/cam4.4765","article-title":"Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed\/refractory mantle cell lymphoma: A multicenter study","volume":"11","author":"Zhang","year":"2022","journal-title":"Cancer Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/ajh.26523","article-title":"Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments","volume":"97","author":"Jain","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"107385","DOI":"10.1016\/j.leukres.2023.107385","article-title":"The shifting therapeutic paradigm for relapsed\/refractory mantle cell lymphoma","volume":"134","author":"Gao","year":"2023","journal-title":"Leuk. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.3324\/haematol.2022.282252","article-title":"Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: A population-based analysis","volume":"108","author":"Di","year":"2023","journal-title":"Haematologica"}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2038-8330\/16\/1\/6\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:49:27Z","timestamp":1760104167000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/16\/1\/6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,18]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["hematolrep16010006"],"URL":"https:\/\/doi.org\/10.3390\/hematolrep16010006","relation":{},"ISSN":["2038-8330"],"issn-type":[{"value":"2038-8330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,18]]}}}